Abstract 13123: Diflunisal is Associated With Improved Mortality in Patients With Wild-Type ATTR Cardiac Amyloidosis: The BU Amyloidosis Center Experience
Yuliya Mints(Boston University), Omar K. Siddiqi(Boston University), Gheorghe Doros(Boston University), Lawreen H. Connors(Boston University), Shivangi Kataria(Indian Institute of Technology Mandi), Deepa M. Gopal(Boston University), Graham Lohrmann(Boston University), Frederick L. Ruberg(Boston University), Alexandra Pipilas(Boston University), John L. Berk(Boston University)
Circulation
November 19, 2019
Cited by 2
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study
|Annals of Internal Medicine|2004|615